Podcasts about Pfizer

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über einen Mega-Deal von Lucid, Billionen-Träume bei Netflix und den Absturz von Jungheinrich. Außerdem geht es um Quantumscape, Bigbear.AI, Aeva Technologies, D-Wave, Archer Aviation, Intuitive Machines, Rocket Lab, AST Spacemobile, Netflix, Disney, ComCast, Warner Brothers Discovery, Uber Technology, Interactive Brokers, TSMC, ASML, PepsiCo, Taiwan Semiconductor, Novartis, Richemont, ABB, Siemens, Salzgitter, Burberry, American Express, Tema Neuroscience and Mental Health ETF (WKN: A408EL), Vertex Pharmaceutical, Eisai, Biogen, Eli Lilly, DexCom, Siemens Healthineers, Johnson&Johnson, Pfizer, Lindbeck, GSK, Atai Life Science, Mind Medicine, iShares Core MSCI World (A0RPWH), Xtrackers MSCI World USD (A1XB5U), Vanguard FTSE All-World USD (A2PKXG), Xtrackers AI & Big Data (A2N6LC), Amundi MSCI World USD (ETF146), Amundi Core Stoxx Europe 600 (LYX0Q0), iShares MSCI ACWI (A1JMDF), Xtrackers II EUR Overnight (DBX0AN), WisdomTree Europe Defence ETF (A40Y9K), HanETF Future of Defence ETF (A3EB9T). Habt Ihr suizidale Gedanken, oder habt Ihr diese bei einem Angehörigen/Bekannten festgestellt? Hilfe bietet die Telefonseelsorge: Anonyme Beratung erhält man rund um die Uhr unter den kostenlosen Nummern 0800 / 111 0 111 und 0800 / 111 0 222. Auch eine Beratung über das Internet ist möglich unter http://www.telefonseelsorge.de. Eine Liste mit bundesweiten Hilfsstellen findet sich auf der Seite der Deutschen Gesellschaft für Suizidprävention. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Bree Groff, an organizational change and culture consultant, keynote speaker, and author of Today Was Fun, joins me on the latest Business Minds Coffee Chat. Bree is one of today's leading voices on the future of work and company culture. Over the course of her career, she has guided executives at companies such as Microsoft, Pfizer, Calvin Klein, Google, and Target through periods of complex change.

My husband has high cholesterol, triglycerides, and blood sugar...help!Is taking Xifaxin and metronidazole an effective treatment for SIBO?I have thyroid antibodies, had COVID twice, and now suffer from fatigueI am 83 years old and my symptoms started after taking the second dose of the Pfizer vaccine in 2021.I've been taking ashwagandha for years for mild anxiety.  Is it okay to continue?

Today on Raise the Line, we bring you the unlikely and inspiring story of a woman who was afraid of blood as a child but became an accomplished nurse; who struggled with learning disabilities but became an effective educator; and who, despite lacking business experience or knowledge of graphics, built a successful company that produces visually rich educational materials for nurses and other providers. “I think the theme of my life has been I have struggled with learning, and I didn't want other people to struggle,” says Jennifer Zahourek, RN, the founder and CEO of RekMed which has developed a sequential, interactive learning system that includes illustrated planners, books, and videos used by millions of students and providers. The initial focus was to provide nurses with everything they needed to know from “the basics to the bedside” but RekMed now offers content for medics, respiratory therapists, medical assistants, and veterinarians as well. Driven by her belief in the power of visual learning and her “just freakin' do it” attitude, Jennifer overcame her fear of launching a business and quickly realized just how well nursing had prepared her for the hard work and unpredictability of entrepreneurship. “Nursing teaches you how to just be resilient, to pivot, to delegate, to work on a team and to handle high stress. I think nurses could literally be some of the best entrepreneurs on the planet,” she tells host Lindsey Smith. Tune in to this lively and valuable conversation as Jennifer shares lessons from bootstrapping a publishing company, insights on the evolving landscape of healthcare education, and advice on embracing change in nursing, especially with the expanding role of AI. Mentioned in this episode:RekMed If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

This episode covers: Cardiology This Week: A concise summary of recent studies ICD Indications in primary prevention Drug treatment of cardiac amyloidosis Mythbusters Host: Rick Grobbee Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana Want to watch that episode? Go to: https://esc365.escardio.org/event/1810   Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Gerhard Hindricks Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1810?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What does it truly mean to lead when the world around you crumbles and rebuilds itself?This episode features host Denis Gianoutsos' most powerful conversations with two extraordinary leaders. Dr. Nadya Zhexembayeva, born to political dissidents in Soviet Kazakhstan, witnessed her world collapse overnight—yet discovered that leadership is a dynamic space we enter and exit, not a fixed title. Ken Miller, a healthcare executive with 32 years of global experience, reveals the athletic mindset required for modern leadership and why our most outstanding teachers are found in our closest relationships, not boardrooms.Join Denis Gianoutsos for this transformative mashup—your perspective on leadership may never be the same.EP 221 - Dr. Nadya Zhexembayeva: Leadership as a Dynamic Space: From Soviet Collapse to Revolutionary ThinkingBorn in Soviet Kazakhstan to political dissidents, witnessed sudden USSR collapse, creating a complete vacuumRedefines leadership as a space you enter and exit daily, not a fixed title or position.Draws from Kazakh nomadic culture,e viewing leadership as a dynamic circle larger than any individualIdentifies daughter and parents as most significant leadership influences, emphasizing self-love before leading othersEP 225 - Ken Miller: Healthcare Leadership and the Athletic Mindset: Building Legacy Through Purpose32 years in healthcare at companies like Sanofi, Pfizer, Roche, choosing impact over just profitDescribes leaders as athletes - highly competitive with a tireless appetite for success and sacrificeEmphasizes continuous learning and personal development rather than relying on organizationsCites Dr. Martin Luther King Jr. as a favorite leader for authenticity and fighting for something bigger than himselfKey Quotes:"Leadership for me is a space. You enter and exit many times a day." - Dr. Nadya Zhexembayeva"You've gotta have a work ethic, which is second to none, to really have an impact around the world." - Ken MillerThe 10 Proven Ways to Lead and Thrive in Today's World - FREE Executive Guide Download https://crm.leadingchangepartners.com/10-ways-to-lead Connect with Denis:Email: denis@leadingchangepartners.comWebsite: www.LeadingChangePartners.com Facebook: https://www.facebook.com/denisgianoutsos LinkedIn: https://www.linkedin.com/in/denisgianoutsos/ Instagram: https://www.instagram.com/leadershipischanging/ YouTube Channel: https://www.youtube.com/@DenisGianoutsos

AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/43029 At the conclusion of this activity, participants will be able to: 1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer 4. Discern the different prognostic endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Šoreiz raidījumā Divas puslodes pārsvarā pievēršamies notikumiem Eiropā. Neuzticības balsojumu pagājušajā nedēļā ir izturējusi Eiropas Komisijas prezidente Urzula fon der Leiena. Lai gan jau pirms balsojuma bija skaidrs, ka jaunas komisijas meklējumos nebūs jādodas, notikums tomēr ir uzmanības vērts, jo izgaismo neapmierinātību ar komisijas vadību, tostarp arī to politisko spēku vidū, kas viņas kandidatūru atbalstīja. Šengenas beigu sākums - šādi virsraksti nereti vērojami starptautiskajos medijos, tiem atspoguļojot Eiropas valstu arvien stingrākos pasākumus imigrācijas ierobežošanai. Vai pārbaudes uz robežām tiešā nozīmē Šengenas nāvi un kad sagaidīsim darbojošos Eiropas mēroga risinājumus imigrācijas kontrolēšanai? Pēc četrām desmitgadēm ieročus nolicis kurdu bruņotais separātistu grupējums Kurdistānas Sstrādnieku partija. Kamēr partija norāda, ka cīņu pārnes uz demokrātisko fronti jeb politiku, Turcijas prezidents Redžeps Tajips Erdogans jau paziņojis, ka atbruņošanās uzskatāma par viņa valsts uzvaru. Kādēļ tas notiek tagad un kurš no tā būs ieguvējs? Nedaudz arī par vē vienu aktualitāti - Tramps izvirzījis Krievijai prasību 50 dienu laikā diplomātiskā ceļā vienoties par mieru, piedraudot, ka pretējā gadījumā uzliks ievedmuitu 100% apmērā importam no Krievijas un no tās tirdzniecības partneriem.  Aktualitātes analizē politisko norišu pētnieks Veiko Spolītis un Latvijas Ārpolitikas institūta asociētais pētnieks Marts Ivaskis.   Fon der Leienas kundzes jaunā pieredze Eiropas Parlamenta balsojumi par neuzticības izteikšanu Eiropas Komisijas prezidentam, respektīvi, komisijai pilnā sastāvā, nav sevišķi bieža parādība. Salīdzinoši vairāk to bija pagājušā gadsimta deviņdesmitajos gados, kad Žaka Delora komisija piedzīvoja trīs, bet Žaka Santēra komisija – divus balsojumus, pie tam Santērs demisionēja pats brīdī, kad brieda trešais balsojums. Mūsu gadsimtā pa vienam balsojumam nācies izturēt Romano Prodi 2004. gadā, Žozē Manuelam Barrozu 2005. gadā un Žanam Klodam Junkeram 2014. gadā. Pagājušajā ceturtdienā, 10. jūlijā, šim sarakstam pievienojusies arī Urzula fon der Leiena. Tāpat kā iepriekšējās reizēs arī šoreiz viss beidzās komisijas labā: 360 parlamentāriešiem balsojot pret, nepieciešamais divu trešdaļu balsu apjoms netika iegūts, un fon der Leienas komisija palika savā vietā. Konkrētais balsojuma rosinātājs bija deputāts no Rumānijas George Piperjs, labējā Eiropas Konservatīvo un reformistu grupā ietilpstošās partijas Alianse rumāņu vienotībai pārstāvis. Galvenais motīvs ir t.s. Faizergeita – skandāls, kuru 2021. gada aprīlī izraisīja laikraksta „The New York Times” publikācija, kurā tika apgalvots, ka vienošanās starp Eiropas Komisiju un farmācijas kompāniju „Pfizer” par 35 miljardus vērto Covid-19 vakcīnu iepirkumu faktiski notikusi, fon der Leienai apmainoties īsziņām ar „Pfizer” izpilddirektoru Albertu Burlu. Eiropas Komisija noliedz šādu traktējumu, savukārt laikraksts panācis Eiropas Vispārējās tiesas lēmumu, ka komisijai būtu jāpadara attiecīgā sarakste publiski pieejama. Visdrīzāk, juridiska stīvēšanās par šo jautājumu, kā arī par to, vai īsziņas vispār var būt obligāti publiskojams materiāls, turpināsies. Pērkot deputātu labvēlību, pirms balsojuma fon der Leienai nācās atteikties no vairākām savām nostādnēm pēc pāris nedēļām apstiprināmā savienības septiņgadu budžeta sakarā. Sociālistu un demokrātu grupa pavisam tieši piedraudēja balsojumā atturēties, ja budžetā netiks saglabāta apjomīgā Eiropas Sociālā fonda finansējuma daļa. Tāpat fon der Leiena atteicās no domas finansējumu reģionu atbalstam, kas veido apmēram trešdaļu no visa savienības budžeta, piešķirt ar nacionālo valdību starpniecību. Pret neuzticības izteikšanu balsoja vairums deputātu no Eiropas Tautas partijas, Sociālistu un demokrātu, liberālās „Atjauno Eiropu” un Zaļo grupām, savukārt par – pamatā labējie: Konservatīvie un reformisti, „Eiropas patrioti”, Suverēno nāciju Eiropa, arī daļa no radikālās Kreiso grupas. Kurdistānas Strādnieku partija noliek ieročus Kurdi ir viena no pasaules lielākajām nācijām bez savas valsts. Aprēķini ir visai atšķirīgi, taču ne mazāk kā trīsdesmit miljoni kurdu kompakti apdzīvo Turcijas dienvidaustrumus, kā arī tiem piegulošos Irānas, Irākas un Sīrijas rajonus. Suverēnas Kurdistānas izveides ideja tika pieteikta jau pirms vairāk nekā simts gadiem, Pirmā pasaules kara izskaņā, taču ne toreiz, ne vēlāk nav īstenojusies. Kurdu neatkarības centienus visas pieminētās valstis uzlūkojušas kā apkarojamu separātismu, un palaikam šī pretstāve izvērtusies bruņotā cīņā. Turcijas kurdu cīņas avangards kopš 1978. gada bija Kurdistānas Strādnieku partija, kuras ideoloģija apvienoja kurdu nacionālismu un marksismu, deklarējot kā mērķi ne vien neatkarīgu, bet arī sociālistisku Kurdistānu. Tiek lēsts, ka organizācijas bruņotā cīņa pret Turciju prasījusi vairāk nekā 37 000 dzīvību, pie tam vardarbībā pret civiliedzīvotājiem tiek vainotas abas puses. 1999. gadā Turcijas specdienestiem izdevās Kenijā sagūstīt un pārvest uz Turciju Kurdistānas Strādnieku partijas dibinātāju un līderi Abdullu Edželanu, kurs kopš tā laika atrodas mūža ieslodzījumā. Pēc Sadama Huseina režīma sabrukuma Irākā 2003. gadā un Sīrijas pilsoņkara uzliesmošanas 2011. gadā kurdu bruņotās vienības sāka kontrolēt savas etniskās teritorijas attiecīgajās valstīs, un šeit patvērumu atrada arī Kurdistānas Strādnieku partijas kaujinieki, kas, savukārt, pamudināja Turciju īstenot militāras operācijas pret kurdu spēkiem kaimiņvalstu teritorijā. 2012. gadā toreizējā Turcijas premjerministra Redžepa Tajipa Erdogana valdība uzsāka sarunas ar ieslodzījumā esošo Edželanu, taču nākamajā gadā Parīzē tika noslepkavots viens no kurdu līderiem, un pāris nākamo gadu laikā miera process izjuka. Šķiet, tagad ir izdevies panāks labāku rezultātu, jo šī gada februārī Edželans aicināja savu organizāciju atbruņoties un pašlikvidēties, un maijā Kurdistānas Strādnieku partijas kongress tiešām pieņēma attiecīgu lēmumu. 11. jūlijā Irākas ziemeļu pilsētā Suleimānijā Strādnieku partijas kaujinieki piedalījās simboliskā ieroču iznīcināšanas ceremonijā, dedzinot sārtā savus automātus un citus šaujamos. Grūti gan spriest, cik liela daļa no Strādnieku partijas militārā spārna ir gatavi pakļauties augstākstāvošo lēmumam un tiešām atbruņoties. Tāpat pagaidām nav skaidri zināms, ko ir apņēmusies darīt Turcijas valdība apmaiņā pret kurdu atteikšanos no bruņotas cīņas.  Vai Šengena briesmās?  Pagājušajā nedēļā prezidents Makrons un premjerministrs Stārmers tikās Londonā kārtējā Francijas un Lielbritānijas samitā. Kā teju nozīmīgākais tikšanās rezultāts tiek izcelta vienošanās par neregulāro imigrantu apmaiņas programmu, proti, Francija piekrīt saņemt no Lielbritānijas atpakaļ zināmu skaitu ārpuseiropas migrantu, kuri bez ieceļošanas atļaujas šķērsojuši Lamanšu, savukārt Lielbritānija uzņems attiecīgu skaitu tādu, kuriem būtu tiesības uz uzturēšanos, bet kuri to līdz šim nav mēģinājuši panākt. Tiek lēsts, ka šādi Lielbritānija varētu nosūtīt atpakaļ uz kontinentu apmēram 2600 cilvēkus gadā jeb apmēram 6% no bez atļaujas atkuģojušajiem. Kamēr briti bija Eiropas Savienībā, viņiem bija tiesības nosūtīt neregulāros migrantus uz to savienības valsti, kurā viņi bija ieradušies vispirms. Līdz 2016. gadam Apvienotā Karaliste nogādāja kontinentā vairāk ieceļotāju nekā uzņēma, taču tagad situācija ir mainījusies. 2024. gadā pieteikumus par uzturēšanās atļaujas piešķiršanu iesnieguši 108 000 cilvēku, kas ir apmēram divas ar pusi reizes vairāk nekā 2018. gadā. Šogad, kā liecina statistika, šis apjoms varētu vēl dubultoties. Pret šiem skaitļiem domājamais atgriežamo daudzums šķiet pieticīgs, taču abi valdību vadītāji izteicās optimistiski – galu galā šī ir pirmā šāda veida vienošanās starp Lielbritāniju pēc Breksita un kādu Eiropas Savienības valsti. Tikām citāda noskaņa valda divu Eiropas Savienības valstu – Polijas un Vācijas – pierobežā pēc tam, kad Polija 7. jūlijā ieviesa daļēju robežas kontroli ar Vāciju un arī Lietuvu. Iemesls jau atkal ir neregulārie migranti, kuri cenšas, ietikuši Polijā vai kādā no Baltijas valstīm, nonākt Vācijā. Taču Varšava diezin vai būtu spērusi šādu soli, ja Berlīne ko līdzīgu nepasāktu jau 2023. gada oktobrī. Šobrīd tās gan ir pārbaudes izlases kārtībā, un teorētiski tām būtu pēc kāda laika jābeidzas, tomēr par to drošas pārliecības nav. Eiropas Savienības likumdošana paredz, ka kontrole uz tās iekšējām robežām var tikt ieviesta tikai ārkārtas situācijās un uz pusgadu, taču norma skaidri nenosaka, ka šo termiņu nevar pagarināt. To arī dara ne vien Vācija un Polija, bet arī vairākas citas dalībvalstis. Situācijā, kad kontrolētas Eiropas Savienības iekšējās robežas tikai vairojas, arvien biežāk izskan spriedelējumi par iespējamu Šengenas sistēmas galu. Sagatavoja Eduards Liniņš.  

Pourquoi faire un focus sur les rachialgies persistantes dans le contexte de la spondyloarthrite ? Quels sont les mécanismes inflammatoires et non-inflammatoires impliqués dans ces douleurs persistantes ? Quelles stratégies thérapeutiques recommandez-vous lorsque les traitements conventionnels échouent ? Le Professeur Thao Pham, Rhumatologue à l'Hôpital Sainte-Marguerite du CHU de Marseille, nous éclaire à ce sujet. Notre invité déclare avoir un lien d'intérêt en rapport avec le sujet traité. L'équipe : Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud Listrat, Dr Nicolas Poursac, Dr Céline Vidal, Dr Margaux Moret. Animation : Marguerite de Rodellec Production : MedShake Studio Soutien institutionnel : Pfizer  

Self proclaimed Democratic Socialist Zohran Mamdani meeting with New York City's leading CEOs who employ thousands at some of the world's biggest companies, such as JPMorgan and Pfizer. Business owners in New York are very concerned about Mamdani's anti-capitalist policies including increasing taxes on the rich to pay for housing rent freezes, free public transit and city run grocery stores. This a day after former Governor Andrew Cuomo says he will be staying in the race despite losing to Mamdani in the primary by a double digit margin. Fox's John Saucier speaks to Bryan Llenas, National Correspondent for FOX News Channel (FNC) based in New York, who says besides the concerns of business owners there are Jewish leaders also sounding the alarm over the candidate's use of the phrase 'globalize the intifada'. Click Here⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

The discovery of “black goo” on a boat in Ohio has created a lot of speculation, especially after it was studied by the University of Minnesota Duluth and found to have “20 DNA sequences... including one that was completely novel.” Black Goo has been seen in countless movies, tv shows, music videos, and even commercials. At its core, the black represents void and abyss, the goo being nothing but an amorphous substance or blank canvas on which to paint anything. On a more literal level, this goo is real, be it faulty asphalt or raw sewage. In the case of what was found in Ohio, it is something very genetically mysterious.  From the X Files and Prometheus the substance is an alien virus or mutagenic pathogen. In District 9 it is a biological agent. In Venom it is a symbiot. In Star Trek it is a conscious of malevolence. In Lucy the substance is a drug that eventually allows for evolution of the chapter into a super-advanced intelligence transcending space and time as a black goo computer - when IBM unveiled their quantum computer it appeared as black goo in a clear black box. A few days previous there were two reports about a creature existing between life and death, and small xenobots operating in human cells after the body has died. The strange creature was called “Sukunaarchaeum mirabile,” a name coming from Japanese mythology: Sukuna & Bikona.  Sukuna translates as “lesser name” or “small" Bikona translates as “divine” or “renown.” The name represses the deity Sukunabikona's diminutive stature and humble or lesser status. It is often depicted as a small figure riding in a tiny boat or working alongside the more prominent deity Ōkuninushi. Boats are vessels of guidance across rivers like Nile or Styx, and they also bring civilizers like Oannes, Osiris, and Quetzalcoatl. A Japanese movie called The Boy and the Heron is the recent release from Studio Ghibili, featuring a heron that acts like Charon on the river Styx. The boat in Ohio that passed black goo was also called the Blue Heron. This black substance can also be found in Princess Mononoke, Howl's Moving Castle, and Spirit Away. The Japanese connection is made strange when learning that scientists from that country were working on the hybrid creature in the X Files episode Nisei, which also means second generate, relating it to the Sukuna and that which generates secondarily. In other words, Sukunabikona and Nisei are the Japanese version of homunculus, or little diminutive human which in biology acts as a symbol of sperm in the microcosm. In the macrocosm it is the comet. It must not be coincidence that since 2017 we have seen three interstellar objects pass  through our solar system: Oumuamua, Borisov and Atlas in July 2025. The latter two were comets, made distinct by their tail, essentially making them sperm - “panspermia” means the chaotic distortion of life from the sperm comet to the egg planet. The black substance has also been part of the Covid narrative, due to something called black fungus that people have coughed up. It is therefore strange to find black substances in Moderna vaccines that were pulled from the market in several prefectures in Japan. We just learned this month that AG Pam Bondi just stopped an investigation into Pfizer, a company she was once legal counsel for. This comes after her dropping the Epstein client list, part of a large intelligence gathering operation and blackmail ring largely run by the MOSSAD of Israel. Things get even strange when considering that Epstein was working on a human engineering project with scientists and genetic researchers. It must not be a coincidence that the Trump administration on day one initiated the next stage of the Stargate project, pertaining to universal cancer shots or that RFK Jr. at the HHS authorized universal and flu vaccine development. The top four leaders at Pfizer and Moderna are 75% Jewish with ties to Israel, just as the Stargate Project is 50% the same. And to top it all off, on July 4, the President existed a black cube with his wife wearing a white dress and a black strap, both of which appear to represent the Tefillin worn by Jews, the very group RFK Jr. says are the least effected by Covid. That cube also appeared to display what looks like the entity in Mission Impossible, i.e., a truth eating digital parasite.   *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Self proclaimed Democratic Socialist Zohran Mamdani meeting with New York City's leading CEOs who employ thousands at some of the world's biggest companies, such as JPMorgan and Pfizer. Business owners in New York are very concerned about Mamdani's anti-capitalist policies including increasing taxes on the rich to pay for housing rent freezes, free public transit and city run grocery stores. This a day after former Governor Andrew Cuomo says he will be staying in the race despite losing to Mamdani in the primary by a double digit margin. Fox's John Saucier speaks to Bryan Llenas, National Correspondent for FOX News Channel (FNC) based in New York, who says besides the concerns of business owners there are Jewish leaders also sounding the alarm over the candidate's use of the phrase 'globalize the intifada'. Click Here⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

Self proclaimed Democratic Socialist Zohran Mamdani meeting with New York City's leading CEOs who employ thousands at some of the world's biggest companies, such as JPMorgan and Pfizer. Business owners in New York are very concerned about Mamdani's anti-capitalist policies including increasing taxes on the rich to pay for housing rent freezes, free public transit and city run grocery stores. This a day after former Governor Andrew Cuomo says he will be staying in the race despite losing to Mamdani in the primary by a double digit margin. Fox's John Saucier speaks to Bryan Llenas, National Correspondent for FOX News Channel (FNC) based in New York, who says besides the concerns of business owners there are Jewish leaders also sounding the alarm over the candidate's use of the phrase 'globalize the intifada'. Click Here⁠⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode, Michael D. Levitt sits down with Justin, founder of Aryo Consulting Group, to unpack small businesses' real-world challenges in today's fast-paced economy. With a track record of helping over 350 companies—ranging from scrappy startups to established enterprises—Justin brings practical insight into what works (and what doesn't) when scaling a business.

Drs. Hope Rugo, Sheri Brenner, and Mikolaj Slawkowski-Rode discuss the struggle that health care professionals experience when terminally ill patients are suffering and approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way. TRANSCRIPT Dr. Hope Rugo: Hello, and welcome to By the Book, a monthly podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book.  I'm your host, Dr. Hope Rugo. I'm director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center, and I'm also the editor-in-chief of the Educational Book. On today's episode, we'll be exploring the complexities of grief and oncology and the struggle we experience as healthcare professionals when terminally ill patients are suffering. Our guests will discuss approaches to help clinicians understand and respond to suffering in a more patient-centered and therapeutic way, as outlined in their recently published article titled, “Oncology and Suffering: Strategies on Coping With Grief for Healthcare Professionals.” I'm delighted today to welcome Dr. Keri Brenner, a clinical associate professor of medicine, palliative care attending, and psychiatrist at Stanford University, and Dr. Mikołaj Sławkowski-Rode, a senior research fellow in philosophy in the Humanities Research Institute at the University of Buckingham, where he also serves as director of graduate research in p hilosophy. He is also a research fellow in philosophy at Blackfriars Hall at the University of Oxford and associate professor at the University of Warsaw.  Our full disclosures are available in the transcript of this episode. Dr. Brenner and Dr. Sławkowski-Rode, thanks for being on the podcast today. Dr. Keri Brenner: Great to be here, Dr. Rugo. Thank you so much for that kind introduction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. It's a pleasure and an honor. Dr. Hope Rugo: So I'm going to start with some questions for both of you. I'll start with Dr. Brenner. You've spoken and written about the concept of suffering when there is no cure. For oncologists, what does it mean to attune to suffering, not just disease? And how might this impact the way they show up in difficult conversations with patients? Dr. Keri Brenner: Suffering is something that's so omnipresent in the work of clinical oncology, and I like to begin by just thinking about what is suffering, because it's a word that we use so commonly, and yet, it's important to know what we're talking about. I think about the definition of Eric Cassell, who was a beloved mentor of mine for decades, and he defined suffering as the state of severe distress that's associated with events that threaten the intactness of a person. And my colleague here at Stanford, Tyler Tate, has been working on a definition of suffering that encompasses the experience of a gap between how things are versus how things ought to be. Both of these definitions really touch upon suffering in a person-centered way that's relational about one's identity, meaning, autonomy, and connectedness with others. So these definitions alone remind us that suffering calls for a person-centered response, not the patient as a pathology, but the panoramic view of who the patient is as a person and their lived reality of illness. And in this light, the therapeutic alliance becomes one of our most active ingredients in care. The therapeutic alliance is that collaborative, trusting bond as persons that we have between clinician and patient, and it's actually one of the most powerful predictors of meaningful outcomes in our care, especially in oncologic care.  You know, I'll never forget my first day of internship at Massachusetts General Hospital. A faculty lecturer shared this really sage insight with us that left this indelible mark. She shared, “As physicians and healers, your very self is the primary instrument of healing. Our being is the median of the medicine.” So, our very selves as embodied, relationally grounded people, that's the median of the medicine and the first most enduring medicine that we offer. That has really borne fruit in the evidence that we see around the therapeutic alliance. And we see this in oncologic care, that in advanced cancer, a strong alliance with one's oncologist truly improves a patient's quality of life, treatment adherence, emotional well-being, and even surpasses structured interventions like psychotherapeutic interventions. Dr. Hope Rugo: That's just incredibly helpful information and actually terminology as well, and I think the concept of suffering differs so much. Suffering comes in many shapes and forms, and I think you really have highlighted that. But many oncologists struggle with knowing what to do when patients are suffering but can't be fixed, and I think a lot of times that has to do with oncologists when patients have pain or shortness of breath or issues like that. There are obviously many ways people suffer. But I think what's really challenging is how clinicians understand suffering and what the best approaches to respond to suffering are in the best patient-centered and therapeutic way. Dr. Keri Brenner: I get that question a lot from my trainees in palliative care, not knowing what to do. And my first response is, this is about how to be, not about knowing what to do, but how to be. In our medical training, we're trained often how to think and treat, but rarely how to be, how to accompany others. And I often have this image that I tell my trainees of, instead of this hierarchical approach of a fix-it mentality of all we're going to do, when it comes to elements of unavoidable loss, mortality, unavoidable sufferings, I imagine something more like accompaniment, a patient walking through some dark caverns, and I am accompanying them, trying to walk beside them, shining a light as a guide throughout that darkness. So it's a spirit of being and walking with. And it's so tempting in medicine to either avoid the suffering altogether or potentially overidentify with it, where the suffering just becomes so all-consuming like it's our own. And we're taught to instead strike a balance of authentic accompaniment through it. I often teach this key concept in my palli-psych work with my team about formulation. Formulation is a working hypothesis. It's taking a step back and asking, “Why? Why is this patient behaving in this manner? What might the patient's core inner struggle be?” Because asking that “why” and understanding the nuanced dimensions of a patient's core inner struggle will really help guide our therapeutic interactions and guide the way that we accompany them and where we choose to shine that light as we're walking with them. And oftentimes people think, “Well Keri, that sounds so sappy or oversentimental,” and it's not. You know, I'm just thinking about a case that I had a couple months ago, and it was a 28-year-old man with gastric cancer, metastatic disease, and that 28-year-old man, he was actually a college Division I athlete, and his dad was an acclaimed Division I coach. And our typical open-ended palliative care questions, that approach, infuriated them. They needed to know that I was showing up confident, competent, and that I was ready, on my A-game, with a real plan for them to follow through. And so my formulation about them was they needed somebody to show up with that confidence and competence, like the Division I athletes that they were, to really meet them and accompany them where they were on how they were going to walk through that experience of illness. Dr. Hope Rugo: These kinds of insights are so helpful to think about how we manage something that we face every day in oncology care. And I think that there are many ways to manage this.  Maybe I'll ask Dr. Sławkowski-Rode one question just that I think sequences nicely with what you're talking about.  A lot of our patients are trying to think about sort of the bigger picture and how that might help clinicians understand and support patients. So, the whole concept of spirituality, you know, how can we really use that as oncology clinicians to better understand and support patients with advanced illness, and how can that help patients themselves? And we'll talk about that in two different ways, but we'll just start with this broader question. Dr. Mikołaj Sławkowski-Rode: I think spirituality, and here, I usually refer to spirituality in terms of religious belief. Most people in the world are religious believers, and it is very intuitive and natural that religious beliefs would be a resource that people who help patients with a terminal diagnosis and healthcare professionals who work with those patients appeal to when they try to help them deal with the trauma and the stress of these situations.  Now, I think that the interesting thing there is that very often the benefit of appealing to a religious belief is misunderstood in terms of what it delivers. And there are many, many studies on how religious belief can be used to support therapy and to support patients in getting through the experience of suffering and defeating cancer or facing a terminal diagnosis. There's a wealth of literature on this. But most of the literature focuses on this idea that by appealing to religious belief, we help patients and healthcare practitioners who are working with them get over the fact and that there's a terminal diagnosis determining the course of someone's life and get on with our lives and engaging with whatever other pursuits we might have, with our job if we're healthcare practitioners, and with the other things that we might be passionate about in our lives. And the idea here is that this is what religion allows us to do because we sort of defer the need to worry about what's going to happen to us until the afterlife or some perspective beyond the horizon of our life here.  However, my view is – I have worked beyond philosophy also with theologians from many traditions, and my view here is that religion is something that does allow us to get on with our life but not because we're able to move on or move past the concerns that are being threatened by illness or death, but by forming stronger bonds with these things that we value in our life in a way and to have a sense of hope that these will be things that we will be able to keep an attachment to despite the threat to our life. So, in a sense, I think very many approaches in the field have the benefit of religion upside down, as it were, when it comes to helping patients and healthcare professionals who are engaged with their illness and treating it. Dr. Hope Rugo: You know, it's really interesting the points that you make, and I think really important, but, you know, sometimes the oncologists are really struggling with their own emotional reactions, how they are reacting to patients, and dealing with sort of taking on the burden, which, Dr. Brenner, you were mentioning earlier. How can oncologists be aware of their own emotional reactions? You know, they're struggling with this patient who they're very attached to who's dying or whatever the situation is, but you want to avoid burnout as an oncologist but also understand the patient's inner world and support them. Dr. Keri Brenner: I believe that these affective, emotional states, they're contagious. As we accompany patients through these tragic losses, it's very normal and expected that we ourselves will experience that full range of the human experience as we accompany the patients. And so the more that we can recognize that this is a normative dimension of our work, to have a nonjudgmental stance about the whole panoramic set of emotions that we'll experience as we accompany patients with curiosity and openness about that, the more sustainable the work will become. And I often think about the concept of countertransference given to us by Sigmund Freud over 100 years ago. Countertransference is the clinician's response to the patient, the thoughts, feelings, associations that come up within us, shaped by our own history, our own life events, those unconscious processes that come to the foreground as we are accompanying patients with illness. And that is a natural part of the human experience. Historically, countertransference was viewed as something negative, and now it's actually seen as a key that can unlock and enlighten the formulation about what might be going on within the patient themselves even. You know, I was with a patient a couple weeks ago, and I found myself feeling pretty helpless and hopeless in the encounter as I was trying to care for them. And I recognized that countertransference within myself that I was feeling demoralized. It was a prompt for me to take a step back, get on the balcony, and be curious about that because I normally don't feel helpless and hopeless caring for my patients. Well, ultimately, I discovered through processing it with my interdisciplinary team that the patient likely had demoralization as a clinical syndrome, and so it's natural many of us were feeling helpless and hopeless also accompanying them with their care. And it allowed us to have a greater interdisciplinary approach and a more therapeutic response and deeper empathy for the patient's plight. And we can really be curious about our countertransferences. You know, a few months ago, I was feeling bored and distracted in a family meeting, which is quite atypical for me when I'm sharing serious illness news. And it was actually a key that allowed me to recognize that the patient was trying to distract all of us talking about inconsequential facts and details rather than the gravitas of her illness.  Being curious about these affective states really allows us to have greater sustainability within our own practice because it normalizes that human spectrum of emotions and also allows us to reduce unconscious bias and have greater inclusivity with our practice because what Freud also said is that what we can't recognize and say within our own selves, if we don't have that self-reflective capacity, it will come out in what we do. So really recognizing and having the self-awareness and naming some of these emotions with trusted colleagues or even within our own selves allows us to ensure that it doesn't come out in aberrant behaviors like avoiding the patient, staving off that patient till the end of the day, or overtreating, offering more chemotherapy or not having the goals of care, doing everything possible when we know that that might result in medically ineffective care. Dr. Hope Rugo: Yeah, I love the comments that you made, sort of weaving in Freud, but also, I think the importance of talking to colleagues and to sharing some of these issues because I do think that oncologists suffer from the fact that no one else in your life wants to hear about dying people. They don't really want to hear about the tragic cases either. So, I think that using your community, your oncology community and greater community within medicine, is an important part of being able to sort of process. Dr. Keri Brenner: Yes, and Dr. Rugo, this came up in our ASCO [Education] Session. I'd love to double click into some of those ways that we can do this that aren't too time consuming in our everyday practice. You know, within palliative care, we have interdisciplinary rounds where we process complex cases. Some of us do case supervision with a trusted mentor or colleague where we bring complex cases to them. My team and I offer process rounds virtually where we go through countertransference, formulation, and therapeutic responses on some tough cases.  You know, on a personal note, just last week when I left a family meeting feeling really depleted and stuck, I called one of my trusted colleagues and just for 3 minutes constructively, sort of cathartically vented what was coming up within me after that family meeting, which allowed me to have more of an enlightened stance on what to do next and how to be therapeutically helpful for the case. One of my colleagues calls this "friend-tors." They coined the phrase, and they actually wrote a paper about it. Who within your peer group of trusted colleagues can you utilize and phone in real time or have process opportunities with to get a pulse check on where what's coming up within us as we're doing this work? Dr. Hope Rugo: Yeah, and it's an interesting question about how one does that and, you know, maintaining that as you move institutions or change places or become more senior, it's really important.  One of the, I think, the challenges sometimes is that we come from different places from our patients, and that can be an issue, I think when our patients are very religious and the provider is not, or the reverse, patients who don't have religious beliefs and you're trying to sort of focus on the spirituality, but it doesn't really ring true. So, Dr. Sławkowski-Rode, what resources can patients and practitioners draw on when they're facing death and loss in the absence of, or just different religious beliefs that don't fit into the standard model? Dr. Mikołaj Sławkowski-Rode: You're absolutely right that this can be an extremely problematic situation to be in when there is that disconnect of religious belief or more generally spiritual engagement with the situation that we're in. But I just wanted to tie into what Dr. Brenner was saying just before. I couldn't agree more, and I think that a lot of healthcare practitioners, oncologists in particular who I've had the pleasure to talk to at ASCO and at other events as well, are very often quite skeptical about emotional engagement in their profession. They feel as though this is something to be managed, as it were, and something that gets in the way. And they can often be very critical of methods that help them understand the emotions and extend them towards patients because they feel that this will be an obstacle to doing their job and potentially an obstacle also to helping patients to their full ability if they focus on their own emotions or the burden that emotionally, spiritually, and in other ways the illness is for the patient. They feel that they should be focusing on the cancer rather than on the patient's emotions. And I think that a useful comparison, although, you know, perhaps slightly drastic, is that of combat experience of soldiers. They also need to be up and running and can't be too emotionally invested in the situation that they're in. But there's a crucial difference, which is that soldiers are usually engaged in very short bursts of activity with the time to go back and rethink, and they often have a lot of support for this in between. Whereas doctors are in a profession where their exposure to the emotions of patients and their own emotions, the emotions of families of patients is constant. And I think that there's a great danger in thinking that this is something to be avoided and something to compartmentalize in order to avoid burnout. I think, in a way, burnout is more sure to happen if your emotions and your attachment to your patients goes ignored for too long. So that's just following up on Keri's absolutely excellent points. As far as the disconnect is concerned, that's, in fact, an area in which I'm particularly interested in. That's where my research comes in. I'm interested in the kinds of connections that we have with other people, especially in terms of maintaining bonds when there is no spiritual belief, no spiritual backdrop to support this connection. In most religious traditions, we have the framework of the religious belief that tells us that the person who we've lost or the values that have become undermined in our life are something that hasn't been destroyed permanently but something that we can still believe we have a deep connection to despite its absence from our life. And how do you rebuild that sense of the existence of the things that you have perceivably lost without the appeal to some sort of transcendent realm which is defined by a given religion? And that is a hard question. That's a question, I think, that can be answered partly by psychology but also partly by philosophy in terms of looking at who we are as human beings and our nature as people who are essentially, or as entities that are essentially connected to one another. That connection, I believe, is more direct than the mediation of religion might at first suggest. I think that we essentially share the world not only physically, it's not just the case that we're all here, but more importantly, the world that we live in is not just the physical world but the world of meanings and values that helps us orient ourselves in society and amongst one another as friends and foes. And it is that shared sense of the world that we can appeal to when we're thinking about retaining the value or retaining the connection with the people who we have lost or the people who are helping through, go through an experience of facing death. And just to finish, there's a very interesting question, I think, something that we possibly don't have time to explore, about the degree of connection that we have with other people. So, what I've just been saying is something that rings more true or is more intuitive when we think about the connections that we have to our closest ones. We share a similar outlook onto the world, and our preferences and our moods and our emotions and our values are shaped by life with the other person. And so, appealing to these values can give us a sense of a continued presence. But what in those relationships where the connection isn't that close? For example, given the topic of this podcast, the connection that a patient has with their doctor and vice versa. In what sense can we talk about a shared world of experience? Well, I think, obviously, we should admit degrees to the kind of relationship that can sustain our connection with another person. But at the same time, I don't think there's a clear cutoff point. And I think part of emotional engagement in medical practice is finding yourself somewhere on that spectrum rather than thinking you're completely off of it. That's what I would say. Dr. Hope Rugo: That's very helpful and I think a very helpful way of thinking about how to manage this challenging situation for all of us.  One of the things that really, I think, is a big question for all of us throughout our careers, is when to address the dying process and how to do that. Dr. Brenner, you know, I still struggle with this – what to do when patients refuse to discuss end-of-life but they're very close to end of life? They don't want to talk about it. It's very stressful for all of us, even where you're going to be, how you're going to manage this. They're just absolutely opposed to that discussion. How should we approach those kinds of discussions? How do we manage that? How do you address the code discussion, which is so important? You know, these patients are not able to stay at home at end-of-life in general, so you really do need to have a code discussion before you're admitting them. It actually ends up being kind of a challenge and a mess all around. You know, I would love your advice about how to manage those situations. Dr. Keri Brenner: I think that's one of the most piercing and relevant inquiries we have within our clinical work and challenges. I often think of denial not as an all-or-nothing concept but rather as parts of self. There's a part of everyone's being where the unconscious believes it's immortal and will live on forever, and yet we all know intellectually that we all have mortality and finitude and transience, and that time will end. We often think of this work as more iterative and gradual and exposure based. There's potency to words. Saying, “You are dying within days,” is a lot higher potency of a phrase to share than, “This is serious illness. This illness is incurable. Time might be shorter than we hoped.” And so the earlier and more upstream we begin to have these conversations, even in small, subtle ways, it starts to begin to expose the patient to the concept so they can go from the head to the heart, not only knowing their prognosis intellectually but also affectively, to integrate it into who they are as a person because all patients are trying to live well while also we're gradually exposing them to this awareness of mortality within their own lived experience of illness. And that, ideally, happens gradually over time. Now, there are moments where the medical frame is very limited, and we might have short days, and we have to uptitrate those words and really accompany them more radically through those high-affective moments. And that's when we have to take a lot of more nuanced approaches, but I would say the more earlier and upstream the better. And then the second piece to that question as well is coping with our own mortality. The more we can be comfortable with our own transience and finitude and limitations, the more we will be able to accompany others through that. And even within my own life, I've had to integrate losses in a way where before I go in to talk to one of my own palliative care patients, one mantra I often say to myself is, “I'm just a few steps behind you. I don't know if it's going to be 30 days or 30 years, but I'm just a few steps behind you on this finite, transient road of life that is the human experience.” And that creates a stance of accompaniment that patients really can experience as they're traversing these tragedies. Dr. Hope Rugo: That's great. And I think those are really important points and actually some pearls, which I think we can take into the clinic. I think being really concrete when really the expected life expectancy is a few days to a couple of weeks can be very, very helpful. And making sure the patients hear you, but also continuing to let them know that, as oncologists, we're here for them. We're not abandoning them. I think that's a big worry for many, certainly of my patients, is that somehow when they would go to hospice or be a ‘no code', that we're not going to support them anymore or treat them anymore. That is a really important process of that as well. And of course, engaging the team makes a big difference because the whole oncology team can help to manage situations that are particularly challenging like that. And just as we close, I wanted to ask one last question of you, Dr. Brenner, that suffering, grief, and burnout, you've really made the point that these are not problems to fix but dimensions that we want to attend to and acknowledge as part of our lives, the dying process is part of all of our lives. It's just dealing with this in the unexpected and the, I think, unpredictability of life, you know, that people take on a lot of guilt and all sorts of things about, all sorts of emotions. And the question is now, people have listened to this podcast, what can they take back to their oncology teams to build a culture that supports clinicians and their team at large to engage with these realities in a meaningful and sustainable way? I really feel like if we could build the whole team approach where we're supporting each other and supporting the patients together, that that will help this process immeasurably. Dr. Keri Brenner: Yes, and I'm thinking about Dr. Sławkowski-Rode's observation about the combat analogy, and it made me recognize this distinction between suppression and repression. Repression is this unconscious process, and this is what we're taught to do in medical training all the time, to just involuntarily shove that tragedy under the rug, just forget about it and see the next patient and move on. And we know that if we keep unconsciously shoving things under the rug, that it will lead to burnout and lack of sustainability for our clinical teams. Suppression is a more conscious process. That deliberate effort to say, “This was a tragedy that I bore witness to. I know I need to put that in a box on the shelf for now because I have 10 other patients I have to see.” And yet, do I work in a culture where I can take that off the shelf during particular moments and process it with my interdisciplinary team, phone a friend, talk to a trusted colleague, have some trusted case supervision around it, or process rounds around it, talk to my social worker? And I think the more that we model this type of self-reflective capacity as attendings, folks who have been in the field for decades, the more we create that ethos and culture that is sustainable because clinician self-reflection is never a weakness, rather it's a silent strength. Clinician self-reflection is this portal for wisdom, connectedness, sustainability, and ultimately transformative growth within ourselves. Dr. Hope Rugo: That's such a great point, and I think this whole discussion has been so helpful for me and I hope for our audience that we really can take these points and bring them to our practice. I think, “Wow, this is such a great conversation. I'd like to have the team as a whole listen to this as ways to sort of strategize talking about the process, our patients, and being supportive as a team, understanding how we manage spirituality when it connects and when it doesn't.” All of these points, they're bringing in how we process these issues and the whole idea of suppressing versus sort of deciding that it never happened at all is, I think, very important because that's just a tool for managing our daily lives, our busy clinics, and everything we manage. Dr. Keri Brenner: And Dr. Rugo, it's reminding me at Stanford, you know, we have this weekly practice that's just a ritual where every Friday morning for 30 minutes, our social worker leads a process rounds with us as a team, where we talk about how the work that we're doing clinically is affecting us in our lives in ways that have joy and greater meaning and connectedness and other ways that might be depleting. And that kind of authentic vulnerability with one another allows us to show up more authentically for our patients. So those rituals, that small 30 minutes once a week, goes a long way. And it reminds me that sometimes slowing things down with those rituals can really get us to more meaningful, transformative places ultimately. Dr. Hope Rugo: It's a great idea, and I think, you know, making time for that in everybody's busy days where they just don't have any time anymore is important. And you don't have to do it weekly, you could even do something monthly. I think there's a lot of options, and that's a great suggestion. I want to thank you both for taking your time out for this enriching and incredibly helpful conversation. Our listeners will find a link to the Ed Book article we discussed today, which is excellent, in the transcript of this episode. I want to thank you again, Dr. Brenner and Dr. Sławkowski-Rode, for your time and for your excellent thoughts and advice and direction. Dr. Mikołaj Sławkowski-Rode: Thank you very much, Dr. Rugo. Dr. Keri Brenner: Thank you. Dr. Hope Rugo: And thanks to our listeners for joining us today. Please join us again next month on By the Book for more insightful views on topics you'll be hearing at the education sessions from ASCO meetings and our deep dives on new approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Hope Rugo @hope.rugo Dr. Keri Brenner @keri_brenner Dr. Mikolaj Slawkowski-Rode @MikolajRode Follow ASCO on social media:      @ASCO on X (formerly Twitter)      ASCO on Bluesky     ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Hope Rugo: Honoraria: Mylan/Viatris, Chugai Pharma Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx Dr. Keri Brenner: No relationships to disclose Dr. Mikolaj Slawkowski-Rode: No relationships to disclose    

1 year anniversary date of the attempted unaliving of now President Trump, still no motive for shooter, who funded it, why nothing was done when a kid was seen on the roof, why CNN chose to air ONLY this rally etc..Epstein Files still a mess, Maxwell offers to testify and disclose the names, but allegedly Republicans now are blocking it.. WTF is happening??Left Coast Libtardia still a disgraceful excuse for an American territory, between protecting illegals, blocking progress of Trump's admin AG Bondi has lost most Americans trust over Epstein and Pfizer defense. DJT keeps going to bat for her but I'm done being patient and being left in the dark about everything There's so much more and it's coming in 24-7 but until the next time…

Jasper van Dijk, Ad Verbrugge en Jelle van Baardewijk bespreken het nieuws van de week.--Meer over de Zomerschool Geopolitiek: https://www.nyenrode.nl/opleidingen/p/strategisch-denken-in-een-onrustige-wereldSteun DNW en word patroon op http://www.petjeaf.com/denieuwewereld.Liever direct overmaken? Maak dan uw gift over naar NL61 RABO 0357 5828 61 t.n.v. Stichting De Nieuwe Wereld. Crypto's doneren kan via https://commerce.coinbase.com/pay/79870e0f-f817-463e-bde7-a5a8cb08c09f-- Bronnen en links bij deze uitzending: - Wierd Duk en Martijntje Smits in gesprek o.l.v. Marianne Zwagerman: https://www.youtube.com/watch?v=ETDYESrvSf4- Paul Krugman over Trump en Bolsonaro: https://paulkrugman.substack.com/p/trumps-dictator-protection-program--00:00 Introductie4:48 Waarom willen jongeren massaal weg uit Nederland?19:50 De huizenmarkt, de VVD en hyperkapitalisme29:15 Tweede Kamer-verkiezingen34:35 Kernwapenalliantie, Oekraïne, Azerbeidzjan en de Israëlische connectie1:01:25 Autoritaire neigingen van Ursula von der Leyen, Pfizer en de EU1:15:15 Pfizer, coronavaccins1:17:40 Kamp voor Palestijnen, VN 2.0, MH-171:35:50 Damen Shipyards1:40:35 Epstein1:43:51 Afronding--De Nieuwe Wereld TV is een platform dat mensen uit verschillende disciplines bij elkaar brengt om na te denken over grote veranderingen die op komst zijn door een combinatie van snelle technologische ontwikkelingen en globalisering. Het is een initiatief van filosoof Ad Verbrugge in samenwerking met anchors Jelle van Baardewijk en Marlies Dekkers. De Nieuwe Wereld TV wordt gemaakt in samenwerking met de Filosofische School Nederland. Onze website: https://denieuwewereld.tv/ DNW heeft ook een Substack. Meld je hier aan: https://denieuwewereld.substack.com/

Has the DOJ actually failed the United States? They fumbled the Epstein case, lied to the American people, and now are closing investigations into some of the most important cases, like Pfizer. It's no wonder rumors are swirling that Dan Bongino and Pam Bondi are experiencing a fallout, with Dan debating resignation. How can our government get anything done when it's not united? Speaking of turmoil, California is once again burning down, figuratively, this time because ICE has taken to raiding another pot farm, which has led to the discovery of child labor. California officials say it's fine, but Tom Homan and everyone else know otherwise. Later, we hit on James Comey and John Brennan being investigated, tensions between the United States and Russia, and Brigitte Macron's defamation lawsuit being overturned. All this and more on today's Untamed!  

Are you looking for a way to take control of your finances but you're not sure where to start?  Tune in for an inspiring discussion with Stephen Ural on his new book Monthly Bill Payment Checklist: The 4-Year Individual and Family Budget Guide, Payment and Expense Tracker, Emergency Fund Planner, Early Debt Payoff Scheduler, and Map to Financial Freedom!Moments with Marianne airs in the Southern California area on KMET 1490AM & 98.1 FM, an ABC Talk News Radio Affiliate!  https://www.kmet1490am.comStephen Ural holds a B.S. in Ecology and an MBA in Finance from Pennsylvania State University. A military veteran with a diverse professional background, including roles in international business finance at Pfizer, real estate investing, and the automotive industry, Stephen recently stepped away from social media to refocus on his true passion: writing to help others. His work reflects deep interests in spirituality, financial responsibility, and the simple joy of being outdoors. He believes personal finance and practical wisdom should be accessible to everyone, especially the lessons schools often leave out. Order Monthly Bill Payment Checklist:  https://a.co/d/5OUvMd7 For more show information visit: https://www.mariannepestana.com

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über einen weiteren Bitcoin-Rekord, abhebende Airline-Aktien und eine Verstärkung des AAA-Teams. Außerdem geht es um United Airlines, Delta Airlines, Expedia Group, Nvidia, Levi Strauss, MP Materials, Ramaco Resources, Vertiv Holdings, Hermès International, Microsoft, Apple, Shelly Group (WKN: A2DGX9), Krka (WKN: 903246), Merck & Co., Pfizer, Nova Ljubljanska Banka (WKN: A2N73H), Petrol (WKN: 903244), Zavarovalnica Triglav (WKN: A0D9FA), Luka Koper (WKN: 923271), Telekom Slovenije (WKN: 915855), Expat Slovenia SBI TOP ETF (WKN A2JB7F), Almonty Industries. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Send us a textAncilla van de Leest spreekt met journalist Ido Dijkstra (De Andere Krant), eindredacteur Ab Gietelink (blckbx), partijleider Tom van Lamoen (Libertaire Partij) en oud-hoogleraar Kees van der Pijl.Arrestatie Arno van KesselIdo Dijkstra praat ons bij over de arrestatie van advocaat Arno van Kessel, die een zaak tegen Bill Gates, Mark Rutte en de staat voerde.Vaccindeal Ursula von der LeyenTom van Lamoen over de Pfizer-deal van Ursula von der Leyen. Waarom zijn de sms'jes over miljarden aan vaccins verdwenen? En waarom haalde de motie van wantrouwen het niet?Wereld in ConflictAb Gietelink analyseert de escalerende spanningen in Oekraïne en het Midden-Oosten. Wat is de impact van de BRICS-top in Rio op het wereldtoneel?BRICS vs. de dollarKees van der Pijl bespreekt hoe BRICS-landen de dollar onder druk zetten. Trump dreigt met importtarieven tegen landen die meegaan in anti-Amerikaans beleid.Support the showWaardeer je deze video('s)? Like deze video, abonneer je op ons kanaal en steun de onafhankelijke journalistiek van blckbx met een donatieWil je op de hoogte blijven?Telegram - https://t.me/blckbxtvTwitter - / blckbxnews Facebook - / blckbx.tv Instagram - ...

“Very often, doctors try to suppress what they feel or don't even have the vocabulary to describe their emotions,” says Professor Alicja Galazka of the University of Silesia, an observation based on decades of work with physicians to enhance their emotional intelligence and resilience. Galazka, a psychotherapist, psychologist, lecturer and coach, believes this deficit is rooted in part in a lack of instruction in the internal and external psychological dimensions of being a medical provider. “There is not enough space created in medical school for teaching and training students about how to deal with their own stress and all of the skills connected to building relationships with patients,” she tells host Michael Carrese. Those same skills are also critical to working effectively as a member of a care team, which is an increasingly common arrangement in hospitals and clinics. Galazka employs simulations, dramatic role-playing, mindfulness, Acceptance and Commitment Therapy and other methods in her work with an eye on increasing the emotional agility and sensitivity of her trainees and clients. Tune in to this thoughtful episode of Raise the Line to hear Galazka's ideas on how to reshape medical training, why she is a proponent of narrative medicine, and the merits of embedding psychologists on care teams as a resource for both patients and providers. Mentioned in this episode:University of SilesiaInternational Association of Coaching Institutes If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

The latest guest on The PR Week podcast is PAN president and CEO Philip Nardone. He talks about the evolution of tech PR and media over the last three decades, as well as recent changes at major agencies. Also on the agenda is the departure of Sally Susman from Pfizer, CEO Mike Doyle leaving Ketchum, WPP's profit warning and a spotlight on the brands responding to tragic flooding in Texas.  AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek

Europees Commissievoorzitter Ursula von der Leyen moet vandaag in het Europees Parlement een vertrouwensstemming overleven. Uiterst rechts verwijt haar een gebrek aan transparantie over de sms'jes die ze in de coronacrisis uitwisselde met de topman van Pfizer om aan vaccins te geraken. Volgens professor Hendrik Vos (UGent) heeft ze die kritiek wat zelf gezocht. Maar ook de centrumpartijen voelen zich ongemakkelijk bij haar autoritaire stijl. Wat is er aan de hand? En kan Von der Leyen blijven voortdoen zoals ze bezig is? ­ Gast Hendrik Vos (UGent) | Presentatie Alexander Lippeveld | Redactie Yves Delepeleire | Eindredactie Bas Schueremans, Alexander Lippeveld | Audioproductie en muziek Brecht Plasschaert | Chef podcast Alexander LippeveldSee omnystudio.com/listener for privacy information.

An Ireland South MEP has defended her decision to vote against what she's called a "fascist" censure vote of the European Commission President. Ursula von der Leyen has survived the motion tabled today after it failed to secure the required two-thirds majority. The motion was brought forward by a Romanian far-right MEP after von der Leyen's refusal to release text messages exchanged with the Chief Executive of Pfizer during the pandemic. Ireland South MEP Fianna Fáil Cynthia Ní Mhurchú has been telling Clare FM's Seán Lyons creating a power vacuum in Europe would only serve to destabilise Ireland and jeopardise its interests.

It's brutal out there. You can build something amazing—beautiful design, flawless code, real value—and still watch it disappear into the crowd. There's this hard truth: building the app is only half the battle. The ones that make it usually combine sharp timing, smart distribution, and a deep understanding of what real users actually need. And in a world where algorithms, privacy rules, and AI keep shifting the ground, staying seen takes more than just a good idea—it takes relentless adaptability. Lior Eldan is the COO and co-founder of Moburst, a global digital marketing agency known for its mobile-first expertise. He's helped brands like Google, Reddit, and Pfizer scale through smart digital strategies. Today, he breaks down the real challenges behind app growth—stressing that building a solid product isn't enough. Eldan highlights the need for sharp user acquisition tactics, app store optimization, and keeping pace with fast-moving tech like AI. His focus: strategy, adaptability, and results-driven marketing. Stay tuned! Resources: Ready to experience hypergrowth? Let's talk! Follow Lior Eldan on Facebook Connect with Lior Eldan on LinkedIn

In this week's episode of the EMJ GOLD Podcast, Matt Mortimer Ryan, Senior Global Marketing Manager, Vaccines, GSK, shares his perspective on how understanding patients' emotional drivers can unlock more impactful, insight-led disease awareness campaigns.  Matt joins Isabel to discuss what true patient-centric marketing looks like in practice, how to translate behavioural insights into smarter strategies, the advice he'd give his younger self and much more.  A little more on EMJ GOLD's guest…  Matt is a global marketing leader at GSK, driven by a passion for human-centered innovation in the pharmaceutical industry. With more than 20 years of experience at GSK, Pfizer and Danone, he combines his scientific curiosity with strategic creativity to accelerate meaningful outcomes for patients. The views expressed in this interview are Matt Mortimer-Ryan's own and do not necessarily represent those of GSK.  

01:03:15 – 01:17:32“One Big Beautiful Bill”: Budget, Amnesty, and Economic FalloutThe new budget bill extends Trump-era tax cuts, slashes welfare and Medicaid, raises defense spending, and increases the debt ceiling by $5 trillion. Critics warn it frontloads benefits and delays cuts, triggering a fiscal cliff by 2028. Despite MAGA promises, the bill includes talk of amnesty and centralizes more power in federal hands. 01:18:29 – 01:21:28Military Budget Passes $1 Trillion MarkThe bill allocates $150 billion in extra military funding, bringing the 2026 military budget to over $1 trillion. Funding priorities include a proposed “Golden Dome” defense system and additional missile stockpiles, sparking concern over boondoggles and unnecessary militarism. 01:29:29 – 01:43:58Inalienable Rights, Tyranny, and the Spirit of 1776A commentary explores the erosion of civil liberties under expanding executive power, comparing modern policies to British tyranny before the American Revolution. Topics include surveillance, indefinite detention, censorship, and the decline of constitutional protections. 01:52:33 – 01:55:35Antidepressant-Linked Suicide and Pfizer LawsuitA widow recounts her husband's suicide shortly after starting Zoloft, leading to a lawsuit against Pfizer. She uncovers internal documents revealing the pharmaceutical company's knowledge of associated risks, sparking wider criticism of industry secrecy. 01:55:35 – 02:00:26Leaked Memo: Pharma Lobby Plots to Silence RFK Jr.A biotech industry memo details efforts to remove RFK Jr. from public discourse due to his challenge to pharmaceutical narratives. Paired with FOIA documents, it exposes widespread media manipulation during the COVID response involving Hollywood, sports leagues, and influencers. 02:17:07 – 02:18:59UK Immigration Criticized as Criminal Crisis by DesignBritish media reports that migrants arriving by boat are far more likely to be imprisoned than UK citizens. Commentary alleges this is part of a deliberate plan to displace native populations and suppress cultural identity. 02:19:30 – 02:21:37Trump to Host UFC Fight at White House as Political SpectaclePlans for a UFC fight at the White House are mocked as emblematic of American political decline and national trivialization. Critics call it a circus undermining presidential dignity. 03:03:16 – 03:05:58Israel Lobby's Push for Bunker Buster Transfers and Nuclear EscalationA bipartisan bill would authorize Trump to transfer stealth bombers and bunker busters to Israel based on Netanyahu's discretion regarding Iran's nuclear intentions. The move is framed as a dangerous escalation and example of unchecked foreign lobbying. 03:06:29 – 03:07:23Pro-Israel Bipartisanship Highlights Uniparty DynamicsDespite differing on abortion and social issues, Reps. Gottheimer and Lawler are united in arming Israel. Commentary criticizes the uniparty system and the U.S. government's prioritization of Israeli military goals. 03:12:14 – 03:16:50Israel Accused of Genocide and Weaponizing StarvationAmnesty International reports Israel is using starvation as a weapon in Gaza, allegedly targeting aid sites to corral and kill civilians. Commentary claims the militarized aid system is designed to enable mass killings with U.S. backing. 03:29:42 – 03:32:40Trump's Mass Amnesty for Migrant Labor CriticizedTrump proposes amnesty for millions of undocumented workers in agriculture and hospitality. Critics call it a betrayal of immigration promises and accuse him of protecting cheap labor for personal business interests. 03:33:58 – 03:41:06Microsoft Lays Off Americans While Expanding H-1B HiringMicrosoft cuts thousands of U.S. jobs while lobbying to expand the H-1B visa cap. Commentary alleges racial hiring bias, credential fraud from foreign diploma mills, and intentional destruction of U.S. tech standards. 03:45:10 – 03:46:51Mexico City Protests American Digital NomadsLocals rally against rising rents and gentrification caused by U.S. digital nomads. The irony is highlighted—Mexicans protest foreign impact while Americans are shamed for raising similar concerns at home. 03:50:31 – 03:52:28Spain Criminalizes Parental Resistance to Gender TransitionNew Spanish law threatens jail time for parents or doctors who oppose a child's gender transition. Critics say the law mandates blind affirmation and criminalizes dissent, especially targeting Christians. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

01:03:15 – 01:17:32“One Big Beautiful Bill”: Budget, Amnesty, and Economic FalloutThe new budget bill extends Trump-era tax cuts, slashes welfare and Medicaid, raises defense spending, and increases the debt ceiling by $5 trillion. Critics warn it frontloads benefits and delays cuts, triggering a fiscal cliff by 2028. Despite MAGA promises, the bill includes talk of amnesty and centralizes more power in federal hands. 01:18:29 – 01:21:28Military Budget Passes $1 Trillion MarkThe bill allocates $150 billion in extra military funding, bringing the 2026 military budget to over $1 trillion. Funding priorities include a proposed “Golden Dome” defense system and additional missile stockpiles, sparking concern over boondoggles and unnecessary militarism. 01:29:29 – 01:43:58Inalienable Rights, Tyranny, and the Spirit of 1776A commentary explores the erosion of civil liberties under expanding executive power, comparing modern policies to British tyranny before the American Revolution. Topics include surveillance, indefinite detention, censorship, and the decline of constitutional protections. 01:52:33 – 01:55:35Antidepressant-Linked Suicide and Pfizer LawsuitA widow recounts her husband's suicide shortly after starting Zoloft, leading to a lawsuit against Pfizer. She uncovers internal documents revealing the pharmaceutical company's knowledge of associated risks, sparking wider criticism of industry secrecy. 01:55:35 – 02:00:26Leaked Memo: Pharma Lobby Plots to Silence RFK Jr.A biotech industry memo details efforts to remove RFK Jr. from public discourse due to his challenge to pharmaceutical narratives. Paired with FOIA documents, it exposes widespread media manipulation during the COVID response involving Hollywood, sports leagues, and influencers. 02:17:07 – 02:18:59UK Immigration Criticized as Criminal Crisis by DesignBritish media reports that migrants arriving by boat are far more likely to be imprisoned than UK citizens. Commentary alleges this is part of a deliberate plan to displace native populations and suppress cultural identity. 02:19:30 – 02:21:37Trump to Host UFC Fight at White House as Political SpectaclePlans for a UFC fight at the White House are mocked as emblematic of American political decline and national trivialization. Critics call it a circus undermining presidential dignity. 03:03:16 – 03:05:58Israel Lobby's Push for Bunker Buster Transfers and Nuclear EscalationA bipartisan bill would authorize Trump to transfer stealth bombers and bunker busters to Israel based on Netanyahu's discretion regarding Iran's nuclear intentions. The move is framed as a dangerous escalation and example of unchecked foreign lobbying. 03:06:29 – 03:07:23Pro-Israel Bipartisanship Highlights Uniparty DynamicsDespite differing on abortion and social issues, Reps. Gottheimer and Lawler are united in arming Israel. Commentary criticizes the uniparty system and the U.S. government's prioritization of Israeli military goals. 03:12:14 – 03:16:50Israel Accused of Genocide and Weaponizing StarvationAmnesty International reports Israel is using starvation as a weapon in Gaza, allegedly targeting aid sites to corral and kill civilians. Commentary claims the militarized aid system is designed to enable mass killings with U.S. backing. 03:29:42 – 03:32:40Trump's Mass Amnesty for Migrant Labor CriticizedTrump proposes amnesty for millions of undocumented workers in agriculture and hospitality. Critics call it a betrayal of immigration promises and accuse him of protecting cheap labor for personal business interests. 03:33:58 – 03:41:06Microsoft Lays Off Americans While Expanding H-1B HiringMicrosoft cuts thousands of U.S. jobs while lobbying to expand the H-1B visa cap. Commentary alleges racial hiring bias, credential fraud from foreign diploma mills, and intentional destruction of U.S. tech standards. 03:45:10 – 03:46:51Mexico City Protests American Digital NomadsLocals rally against rising rents and gentrification caused by U.S. digital nomads. The irony is highlighted—Mexicans protest foreign impact while Americans are shamed for raising similar concerns at home. 03:50:31 – 03:52:28Spain Criminalizes Parental Resistance to Gender TransitionNew Spanish law threatens jail time for parents or doctors who oppose a child's gender transition. Critics say the law mandates blind affirmation and criminalizes dissent, especially targeting Christians. Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über die Angst vor Zollbriefen, die Favoriten der YOLO-Community und die Gewinner der One Big Beautiful Bill. Außerdem geht es um Aeva Technologies, Carvana, Avis, Hertz, WisdomTree NASDAQ 100 3x Daily Leveraged (WKN: A3GL7E), Caterpillar, Dow, Amgen, Pfizer, Johnson&Johson, Verizon, UPS, Altria, Tyson Foods, LyondellBasell, Lockheed Martin, General Dynamics, Northrop Grumman, Munich Re (Münchener Rück), Hannover Rück, Rheinmetall, iShares Edge MSCI USA Value Factor ETF (WKN: A2AP35), Nvidia, Apple, Amazon, BYD, Xiaomi, Alphabet, Palantir, D-Wave Quantum, Renk, Hensoldt, Allianz, Deutsche Bank, Siemens Energy, Thyssenkrupp, Deutsche Telekom, Mercedes-Benz, Volkswagen, Strategy, Coinbase, Commerzbank und Aena. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

From defining what real-world evidence is to discussing its impact on cancer drug approvals, comparative effectiveness, and synthetic data, Dr. Winson Cheung shares insights with Dr. Aly-Khan Lalani and Dr. Christopher Wallis that every clinician should know.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

In our final ASCO 2025 episode, Michael is joined by Prof Jeanne Tie, colorecal cancer lead at Peter MacCallum Cancer Centre to discuss some of the many highlights in colorectal and anal cancer. Starting with the practice changing BREAKWATER study, combining chemotherapy with encorafenib and cetuximab, they also discuss the plenary study ATOMIC III, the CHALLENGE study examining structured exercise programs for patients with resected cancer, as well as the emerging role of ctDNA in colon and anal SCC. Studies discussed in this episodeBREAKWATERCHALLENGEATOMIC IIIINTERAACT 2DYNAMIC IIIFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Are we truly the freest country when it comes to speech - or are we just better at hiding the censorship? In this episode of The Brian Nichols Show, we dig deep into the reality of free speech in America versus the rest of the world - and it's probably not what you've been told. From corporate collusion during COVID to the dangerous misuse of "antisemitism" as a political weapon, this conversation isn't just timely - it's urgent. Studio Sponsor: Cardio Miracle - "Unlock the secret to a healthier heart, increased energy levels, and transform your cardiovascular fitness like never before.": CardioMiracle.com/TBNS Why do we protect offensive speech in the first place? Is there real value in letting unpopular or even "unsavory" opinions into the public square? Gary Frankel, a policy researcher and fierce defender of civil liberties, joins me to unpack America's First Amendment uniqueness - and whether that protection is really as ironclad as we think. But it's not all sunshine and freedom. We explore how both the left and the right are increasingly playing the censorship game - not always with government power, but with cultural influence and legal threats. And yes, we hit the hypocrisy of Big Media being "brought to you by Pfizer" while telling you what information is safe to consume. We also zoom out globally - from the UK's criminalization of Facebook posts to Poland's cultural pushback - and compare how nations handle speech when cultures collide. Spoiler alert: Europe is 0-for-2 on protecting liberty. This is a no-BS, common-sense breakdown of where free speech really stands. If you value open dialogue, healthy disagreement, and freedom from government-mandated narratives, this is the episode you need to hear. ❤️ Order Cardio Miracle (CardioMiracle.com/TBNS) for 15% off and take a step towards better heart health and overall well-being!

Are we truly the freest country when it comes to speech - or are we just better at hiding the censorship? In this episode of The Brian Nichols Show, we dig deep into the reality of free speech in America versus the rest of the world - and it's probably not what you've been told. From corporate collusion during COVID to the dangerous misuse of "antisemitism" as a political weapon, this conversation isn't just timely - it's urgent. Studio Sponsor: ⁠Cardio Miracle⁠ - "Unlock the secret to a healthier heart, increased energy levels, and transform your cardiovascular fitness like never before.": ⁠CardioMiracle.com/TBNS⁠ Why do we protect offensive speech in the first place? Is there real value in letting unpopular or even "unsavory" opinions into the public square? Gary Frankel, a policy researcher and fierce defender of civil liberties, joins me to unpack America's First Amendment uniqueness - and whether that protection is really as ironclad as we think. But it's not all sunshine and freedom. We explore how both the left and the right are increasingly playing the censorship game - not always with government power, but with cultural influence and legal threats. And yes, we hit the hypocrisy of Big Media being "brought to you by Pfizer" while telling you what information is safe to consume. We also zoom out globally - from the UK's criminalization of Facebook posts to Poland's cultural pushback - and compare how nations handle speech when cultures collide. Spoiler alert: Europe is 0-for-2 on protecting liberty. This is a no-BS, common-sense breakdown of where free speech really stands. If you value open dialogue, healthy disagreement, and freedom from government-mandated narratives, this is the episode you need to hear. We have a new show on Lions of Liberty! The Politicks Podcast! Be sure to subscribe to the standalone Politicks Podcast feed. This is the absolute best way to support the show! Listen and subscribe on Apple Podcasts and Spotify. And remember, they're all Blood Suckers! Order ⁠Cardio Miracle⁠ (⁠CardioMiracle.com/TBNS⁠) for 15% off and take a step towards better heart health and overall well-being! Submit Listener Questions to ⁠brian@briannicholsshow.com⁠ to hear your questions and perspectives answered and shared each and every week! WATCH The Brian Nichols Show, available on ⁠YouTube⁠ & ⁠Rumble⁠. With over 985 episodes featuring local candidates, elected officials, economists, CEOs, and more, each show educates, enlightens, and informs.Follow Brian on social media: X.com/Twitter ⁠(https://www.briannicholsshow.com/twitter⁠) & Facebook (⁠https://www.briannicholsshow.com/facebook⁠) Don't forget to like, share, and subscribe to ⁠The Brian Nichols Show ⁠for more captivating interviews and insights into common sense solutions for local problems! Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode covers: Cardiology This Week: A concise summary of recent studies Big data in cardiology Measuring lipids: what clinicians need to know Milestones Host: Perry Elliott Guests: Carlos Aguiar, Karim Lekadir, Kostas Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/1808 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors.  This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Kostas Koskinas has declared to have potential conflicts of interest to report: speaker fees / honoraria from MSD, Daiichi-Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Karim Lekadir Want to watch that episode? Go to: https://esc365.escardio.org/event/1808?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Karim Lekadir have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson."

Jenner Marcucci is the founder of Summit Leadership Group. He has extensive expertise in the areas of leadership development, sales training, communication skills, and executive team development. Most recently, Jenner served as Vice President, Learning & Development for Catalina Marketing – $600M company specializing in personalized digital media. Prior to that, Jenner worked for16 years at Pfizer Inc. in sales, key accounts, sales training, sales management, operations and leadership development. Jenner was instrumental in creating, launching, and implementing Pfizer's worldwide leadership development strategy. Pfizer was recognized as the number one training company in the world for three consecutive years with a field force of 15,000 in the US. Jenner holds a BS in International Business and Spanish from Brigham Young University. He served a 2 year volunteer mission in Madrid Spain. He is fluent in Spanish and has conducted multi-lingual training in Spanish, Italian, Japanese, German, and French. His international clients are diverse and include those from Japan, Mexico, UK, Italy, Germany, France, Denmark, Switzerland, Russia and Australia. His favorite career is being a husband and fathe to five children and three grandchildren. Currently his wife Meridith has placed him on a performance improvement plan. Podcast Sponsor: Summit Leadership Group Summit Leadership Group transforms organizations by developing bold, agile leaders who inspire performance and lead with purpose. Through tailored coaching and immersive training, we ignite lasting growth where it matters most—at the intersection of people, culture, and results. To know more about Jenner visit his website: www.summitleadershipgroup.com

Content managed by ContentSafe.coSupport the show

NYC democrat/socialist mayoral candidate Zohran Mamdani's 5 minutes of fame may be up. The New York Post editorial board delivers a blistering takedown of the 33 year old alderman who believes in wealth re-distribution and unfairly punishing white New Yorkers. Pfizer delays its heart-damage study from its Covid-19 jab until 2030. Dilbert creator Scott Adams drops a monster bunker buster news bomb.

This week Lisa Bodell, Top-50 ranked futurist, author, speaker and founder of FutureThink joins the Futurists. Bodell shares how she teaches structured scenario planning and why “real futurists use models, not guesses”. We discuss scenario planning at Pfizer, that eliminated thousands of hours through their “kill a stupid rule” initiative, and how AI will lead to more meaningful work and less of it. Brett hosts this one solo from Dubai with Lisa in Westchester, NY. 

In this powerful episode of the Medical Sales U Podcast, I sit down with Nick Rich—cancer survivor, AYA advocate, and now a Senior Oncology Account Specialist at Pfizer. Nick opens up about his deeply personal journey from battling cancer to building a career in oncology sales, where he now helps bring life-saving treatments to patients fighting the very diseases he once faced.We discuss how his diagnosis shaped his purpose, the pivotal moments that led him into medical sales, and how his fundraising team helped raise over $50,000 for the Leukemia and Lymphoma Society. You'll hear the grit behind his transition from patient to professional, and how he channels his pain into purpose every day on the job.Whether you're in sales, healthcare, or simply looking for inspiration, this conversation will move you. Nick's story is a testament to resilience, faith, and the impact of using your story to serve others.

Nurses Out Loud – In Part 2 of “Poisoning the Well,” nurses reveal Pfizer's concealed pregnancy trial data, expose misleading “magic math,” and call for full transparency via anonymized raw results. Urgently challenging tough conversations, they urge better questions to bridge divides, examine multigenerational risks for mothers and daughters, and warn of growing psychological fallout unless accountability is demanded...

Nurses Out Loud – In Part 2 of “Poisoning the Well,” nurses reveal Pfizer's concealed pregnancy trial data, expose misleading “magic math,” and call for full transparency via anonymized raw results. Urgently challenging tough conversations, they urge better questions to bridge divides, examine multigenerational risks for mothers and daughters, and warn of growing psychological fallout unless accountability is demanded...

We begin with a free-for-all Friday rundown of the latest news stories about the terrible reconciliation bill, bad endorsements from Trump, and more signs of stagflation. The court decision against universal injunctions is one positive story, but there is a huge catch. Also, why is the new CDC director unquestionably defending mRNA shots? Why is this administration continuing the biomedical security state under the mantle of MAHA? Indeed, there is a difference between MAHA and the “medical freedom movement," like the difference between a sword and a shield. We're joined by Hebrew University professor Josh Guetzkow, who just published a pre-print study of a massive population of pregnant women in Israel showing a shocking safety signal from the COVID shots. The COVID shots were associated with a significant increase in fetal deaths among pregnant women who received the shot during the first trimester. Josh discusses how his study is the most airtight to date and how this signal has been ignored until now. He also reviews his findings from two years ago on how the shots given to the public by Pfizer are not the ones studied in clinical trials, yet even the Trump administration continues to assert that they have been studied and properly approved.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Criminal Complaint Filed Over 'Warp Speed Cancer' (01:00:45 – 01:07:05)A complaint filed in France alleges mRNA vaccines caused deadly turbo cancers, implicating global health agencies while ignoring U.S. officials who enabled vaccine rollout. The term 'Warp Speed Cancer' is used to link aggressive cancers with the vaccine campaign.FDA Study Finds Excess DNA in COVID Vaccines (01:12:06 – 01:14:00)An FDA study confirms high levels of DNA contamination in Pfizer's mRNA vaccine, raising concerns over cancer risk and regulatory negligence. Critics compare the lax response to how pollution or car emissions would be handled.COVID Vaccine Removed from CDC Schedule for Children (01:25:54 – 01:27:49)RFK Jr. announces removal of COVID vaccines from the CDC schedule for healthy children and pregnant women, though skepticism is expressed over the true intent and lingering influence of vaccine advocates.CDC Panel Head Accused of Downplaying Vaccine Injuries (01:33:12 – 01:36:50)The new CDC vaccine panel head is criticized for opposing pauses on J&J shots and ignoring adverse event reports, leading to claims of pro-vaccine bias and lack of transparency about injury risks.Cargo Ship Fire Tied to EV Battery Hazards (01:53:00 – 01:59:30)An EV-laden cargo ship sinks after a prolonged fire, raising environmental concerns over lithium battery safety and whether such incidents are factored into EVs' environmental impact.Tesla Robo-Taxi Glitches Spark Regulatory Scrutiny (02:00:36 – 02:07:42)Videos show Tesla's driverless taxis behaving erratically, including stopping in intersections and veering off course. Observers criticize the premature rollout and ineffective safety measures.Markets Shrug Off U.S.-Israel Strike on Iran (02:25:30 – 02:27:04)Gold, silver, oil, and Bitcoin show minimal reaction to joint U.S.-Israel strikes, suggesting either disbelief in the severity of events or market manipulation by major financial actors.Christian Zionism Criticized as Political Idolatry (02:48:33 – 02:52:57)Christian Zionism is condemned as a distortion of theology, accused of leading believers to support war and foreign interventions at the expense of persecuted Christian communities.Pro-Israel Loyalty Test in Conservative Politics (02:52:58 – 03:01:38)Conservative figures are accused of prioritizing loyalty to Israel over American interests. A generational shift is predicted as younger conservatives push back against foreign entanglements.BIS vs IMF: Stablecoin Suppression and CBDC Agenda (03:01:39 – 03:03:04)The BIS targets stablecoins in what's described as a battle over who will control future digital money, with CBDCs positioned as tools of global financial dominance.Bitcoin Seen as Hedge Against Fiat Collapse (03:03:05 – 03:07:01)Extreme Bitcoin price forecasts are discussed in the context of fiat currency debasement, with Bitcoin framed as a finite refuge from an increasingly unstable monetary system.Self-Driving Cars as Surveillance and Control Tools (03:13:14 – 03:18:00)Explores how autonomous vehicles collect and transmit driver data, affect social credit scores, and raise concerns about accountability, privacy, and control.War Powers Debate: Trump, Iran, and Congressional Authority (03:18:01 – 03:24:17)Critiques Trump's bombing of Iran without Congressional approval and rebuts claims by Mike Johnson and J.D. Vance that the War Powers Resolution limits presidential authority.MAGA Civil War: Candace Owens vs. Trump on Vaccines and Israel (03:24:18 – 03:29:55) Candace Owens distances herself from Trump over foreign policy while she gave him a pass on Warp Speed vaccines, with commentary on her past praise and growing populist pushback.Trump's Nobel Peace Prize Nomination Mocked (03:30:40 – 03:31:35) Trump is nominated for a Nobel Peace Prize following the Iran ceasefire, provoking ridicule given his role in launching strikes days earlier.Mark Levin vs. Steve Bannon: Neocon Populist Feud over Israel (03:34:20 – 03:39:01)Levin calls for escalated military support for Israel, while Bannon and populist circles reject U.S. involvement. The rift signals deeper ideological divides on the right.Damage from Iranian Missile Strikes on Israel (03:45:10 – 03:47:55)Reports and footage highlight destruction caused by Iranian retaliation, while commentary accuses elites of profiting from wars at civilian expense.Iranian Officials Reported Dead Resurface (03:48:40 – 03:50:35) High-ranking Iranian figures previously declared dead by Israeli sources are shown to be alive, raising doubts about the success of targeted strikes.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Criminal Complaint Filed Over 'Warp Speed Cancer' (01:00:45 – 01:07:05)A complaint filed in France alleges mRNA vaccines caused deadly turbo cancers, implicating global health agencies while ignoring U.S. officials who enabled vaccine rollout. The term 'Warp Speed Cancer' is used to link aggressive cancers with the vaccine campaign.FDA Study Finds Excess DNA in COVID Vaccines (01:12:06 – 01:14:00)An FDA study confirms high levels of DNA contamination in Pfizer's mRNA vaccine, raising concerns over cancer risk and regulatory negligence. Critics compare the lax response to how pollution or car emissions would be handled.COVID Vaccine Removed from CDC Schedule for Children (01:25:54 – 01:27:49)RFK Jr. announces removal of COVID vaccines from the CDC schedule for healthy children and pregnant women, though skepticism is expressed over the true intent and lingering influence of vaccine advocates.CDC Panel Head Accused of Downplaying Vaccine Injuries (01:33:12 – 01:36:50)The new CDC vaccine panel head is criticized for opposing pauses on J&J shots and ignoring adverse event reports, leading to claims of pro-vaccine bias and lack of transparency about injury risks.Cargo Ship Fire Tied to EV Battery Hazards (01:53:00 – 01:59:30)An EV-laden cargo ship sinks after a prolonged fire, raising environmental concerns over lithium battery safety and whether such incidents are factored into EVs' environmental impact.Tesla Robo-Taxi Glitches Spark Regulatory Scrutiny (02:00:36 – 02:07:42)Videos show Tesla's driverless taxis behaving erratically, including stopping in intersections and veering off course. Observers criticize the premature rollout and ineffective safety measures.Markets Shrug Off U.S.-Israel Strike on Iran (02:25:30 – 02:27:04)Gold, silver, oil, and Bitcoin show minimal reaction to joint U.S.-Israel strikes, suggesting either disbelief in the severity of events or market manipulation by major financial actors.Christian Zionism Criticized as Political Idolatry (02:48:33 – 02:52:57)Christian Zionism is condemned as a distortion of theology, accused of leading believers to support war and foreign interventions at the expense of persecuted Christian communities.Pro-Israel Loyalty Test in Conservative Politics (02:52:58 – 03:01:38)Conservative figures are accused of prioritizing loyalty to Israel over American interests. A generational shift is predicted as younger conservatives push back against foreign entanglements.BIS vs IMF: Stablecoin Suppression and CBDC Agenda (03:01:39 – 03:03:04)The BIS targets stablecoins in what's described as a battle over who will control future digital money, with CBDCs positioned as tools of global financial dominance.Bitcoin Seen as Hedge Against Fiat Collapse (03:03:05 – 03:07:01)Extreme Bitcoin price forecasts are discussed in the context of fiat currency debasement, with Bitcoin framed as a finite refuge from an increasingly unstable monetary system.Self-Driving Cars as Surveillance and Control Tools (03:13:14 – 03:18:00)Explores how autonomous vehicles collect and transmit driver data, affect social credit scores, and raise concerns about accountability, privacy, and control.War Powers Debate: Trump, Iran, and Congressional Authority (03:18:01 – 03:24:17)Critiques Trump's bombing of Iran without Congressional approval and rebuts claims by Mike Johnson and J.D. Vance that the War Powers Resolution limits presidential authority.MAGA Civil War: Candace Owens vs. Trump on Vaccines and Israel (03:24:18 – 03:29:55) Candace Owens distances herself from Trump over foreign policy while she gave him a pass on Warp Speed vaccines, with commentary on her past praise and growing populist pushback.Trump's Nobel Peace Prize Nomination Mocked (03:30:40 – 03:31:35) Trump is nominated for a Nobel Peace Prize following the Iran ceasefire, provoking ridicule given his role in launching strikes days earlier.Mark Levin vs. Steve Bannon: Neocon Populist Feud over Israel (03:34:20 – 03:39:01)Levin calls for escalated military support for Israel, while Bannon and populist circles reject U.S. involvement. The rift signals deeper ideological divides on the right.Damage from Iranian Missile Strikes on Israel (03:45:10 – 03:47:55)Reports and footage highlight destruction caused by Iranian retaliation, while commentary accuses elites of profiting from wars at civilian expense.Iranian Officials Reported Dead Resurface (03:48:40 – 03:50:35) High-ranking Iranian figures previously declared dead by Israeli sources are shown to be alive, raising doubts about the success of targeted strikes.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

A new study coauthored by Dr. Vibeke Manniche shows birth rates plummeted in 2022. The Czech study reveals women vaccinated for COVID-19 had significantly lower conception rates than unvaccinated women from June 2021 to 2023. Using nationwide data from the Institute of Health Information and Statistics, researchers analyzed 1.3 million women aged 18-39. By late 2021, 70% were vaccinated, mostly with Pfizer or Moderna mRNA shots. By 2022, conception rates were 1.5 times higher in unvaccinated women. Dr. Vibeke Manniche, MD, PhD, is a Danish epidemiologist and author of 35 books on health and family. She opposed COVID lockdowns, citing disproportionate measures. More at https://x.com/mannichevibeke Jeffrey Tucker is Founder and President of the Brownstone Institute. He is also Senior Economics Columnist for Epoch Times, author of 10 books, including Liberty or Lockdown, and thousands of articles in the scholarly and popular press. He speaks widely on topics of economics, technology, social philosophy, and culture. Follow him at https://x.com/jeffreyatucker and https://brownstone.org/ 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/skinrepair⁠⁠⁠⁠⁠⁠⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at ⁠⁠⁠https://vshredmd.com/⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices